Deciphera Pharmaceuticals... (DCPH)
25.59
0.02 (0.08%)
At close: Jun 10, 2024, 8:00 PM
0.08% (1D)
| Bid | n/a |
| Market Cap | 2.21B |
| Revenue (ttm) | 174.91M |
| Net Income (ttm) | -190.42M |
| EPS (ttm) | -2.21 |
| PE Ratio (ttm) | -11.57918552036199 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | n/a |
| Volume | 1,572,857 |
| Avg. Volume (20D) | 1,855,995 |
| Open | 25.56 |
| Previous Close | 25.57 |
| Day's Range | 25.56 - 25.61 |
| 52-Week Range | 9.90 - 25.61 |
| Beta | 0.18 |
About DCPH
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. Th...
Sector Healthcare
IPO Date Sep 28, 2017
Employees 355
Stock Exchange NASDAQ
Ticker Symbol DCPH
Website https://www.deciphera.com
Analyst Forecast
According to 5 analyst ratings, the average rating for DCPH stock is "Hold." The 12-month stock price forecast is $25.6, which is an increase of 0.04% from the latest price.
Stock Forecasts